Compare FRAF & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | HELP |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.8M | 249.0M |
| IPO Year | 1995 | N/A |
| Metric | FRAF | HELP |
|---|---|---|
| Price | $58.75 | $5.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 31.3K | ★ 688.4K |
| Earning Date | 04-23-2026 | 07-01-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $12.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.44 | $4.29 |
| 52 Week High | $58.64 | $8.55 |
| Indicator | FRAF | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 69.27 | 57.24 |
| Support Level | $47.15 | $4.40 |
| Resistance Level | N/A | $8.55 |
| Average True Range (ATR) | 1.78 | 0.30 |
| MACD | 0.45 | 0.13 |
| Stochastic Oscillator | 90.09 | 79.09 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.